

JosÃ© Palacios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5616680/publications.pdf>

Version: 2024-02-01

55
papers

4,960
citations

136950

32
h-index

144013

57
g-index

59
all docs

59
docs citations

59
times ranked

7518
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. <i>Cancer Research</i> , 2008, 68, 989-997.	0.9	934
2	Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. <i>American Journal of Pathology</i> , 1993, 142, 987-93.	3.8	288
3	Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition. <i>Cancer Research</i> , 2006, 66, 9543-9556.	0.9	285
4	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
5	MicroRNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. <i>Journal of Pathology</i> , 2011, 223, 72-80.	4.5	194
6	Epigenetic and genetic alterations of <i>APC</i> and <i>CDH1</i> genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability. <i>International Journal of Cancer</i> , 2003, 106, 208-215.	5.1	186
7	Cytoplasmic localization of p120 ^{ctn} and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. <i>Oncogene</i> , 2004, 23, 3272-3283.	5.9	185
8	The morphological and molecular features of the epithelial-to-mesenchymal transition. <i>Nature Protocols</i> , 2009, 4, 1591-1613.	12.0	185
9	Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. <i>Journal of Pathology</i> , 2005, 207, 1-13.	4.5	172
10	Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. <i>Journal of Pathology</i> , 2008, 215, 231-244.	4.5	153
11	β -Catenin Expression Pattern, β -Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas. <i>Diagnostic Molecular Pathology</i> , 2001, 10, 116-122.	2.1	138
12	Genomic and mutational profiling of ductal carcinomas <i>in situ</i> and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection. <i>Journal of Pathology</i> , 2012, 227, 42-52.	4.5	138
13	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013, 37, e1-e11.	3.7	137
14	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. <i>Annals of Oncology</i> , 2012, 23, 625-631.	1.2	106
15	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. <i>Cancer</i> , 2001, 92, 2829-2836.	4.1	103
16	The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma. <i>Modern Pathology</i> , 2001, 14, 650-654.	5.5	85
17	MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes. <i>PLoS ONE</i> , 2012, 7, e47709.	2.5	85
18	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 56295-56308.	1.8	83

#	ARTICLE	IF	CITATIONS
19	Frequent E-cadherin Gene Inactivation by Loss of Heterozygosity in Pleomorphic Lobular Carcinoma of the Breast. <i>Modern Pathology</i> , 2003, 16, 674-678.	5.5	81
20	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 1390-1398.	5.5	80
21	Pathogenetic Pathways in Ovarian Endometrioid Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1157-1163.	3.7	72
22	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. <i>Human Pathology</i> , 2006, 37, 1042-1049.	2.0	69
23	ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. <i>Modern Pathology</i> , 2013, 26, 1514-1524.	5.5	68
24	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. <i>Journal of Pathology</i> , 2014, 232, 319-329.	4.5	66
25	Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 443-454.	3.1	66
26	E-cadherin expression in basal cell carcinoma. <i>British Journal of Cancer</i> , 1994, 69, 157-162.	6.4	65
27	Functional characterization of E- and P-cadherin in invasive breast cancer cells. <i>BMC Cancer</i> , 2009, 9, 74.	2.6	61
28	Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma. <i>Cancers</i> , 2019, 11, 964.	3.7	54
29	VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 587-599.	3.1	53
30	Zeb1 and <i>S</i> naill engage miR-200f transcriptional and epigenetic regulation during EMT. <i>International Journal of Cancer</i> , 2015, 136, E62-73.	5.1	52
31	Mismatch Repair Deficiency in Ovarian Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 649-656.	3.7	44
32	β -Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 599-604.	2.8	41
33	Apical mitochondria-rich cells in the human epididymis: An ultrastructural, enzymohistochemical, and immunohistochemical study. <i>The Anatomical Record</i> , 1991, 231, 82-88.	1.8	33
34	High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. <i>Cancers</i> , 2019, 11, 74.	3.7	33
35	Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. <i>Oncogene</i> , 2016, 35, 2777-2788.	5.9	31
36	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. <i>Human Pathology</i> , 2013, 44, 244-254.	2.0	30

#	ARTICLE	IF	CITATIONS
37	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. <i>Cancers</i> , 2020, 12, 1832.	3.7	30
38	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. <i>Modern Pathology</i> , 2015, 28, 1492-1503.	5.5	23
39	The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 149-161.	3.7	21
40	Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2020-207337.	2.0	18
41	RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. <i>Frontiers in Microbiology</i> , 2022, 13, 824967.	3.5	18
42	Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 1-15.	2.2	15
43	Prognostic relevance of estrogen receptor- β Ser167 phosphorylation in stage II-III colon cancer patients. <i>Human Pathology</i> , 2014, 45, 2437-2446.	2.0	13
44	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7398.	4.1	13
45	Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 195-207.	2.8	12
46	Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. <i>Thorax</i> , 2021, 76, 1044-1046.	5.6	12
47	Neuropathological findings in fatal COVID-19 and their associated neurological clinical manifestations. <i>Pathology</i> , 2022, 54, 738-745.	0.6	12
48	Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature. <i>Diagnostic Pathology</i> , 2018, 13, 62.	2.0	11
49	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021, 13, 5416.	3.7	7
50	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2018, 20, 274-285.	2.4	5
51	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. <i>Cancers</i> , 2022, 14, 1151.	3.7	5
52	Modified SureSelectQXT Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples. <i>Biological Procedures Online</i> , 2018, 20, 19.	2.9	4
53	Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 233.	3.7	4
54	Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer. <i>Diagnostic Pathology</i> , 2020, 15, 84.	2.0	3

#	ARTICLE	IF	CITATIONS
55	Immune-related gene expression signatures: a step forward in the stratification of patients with ovarian clear cell carcinoma. Journal of Pathology, 2021, , .	4.5	0